Cyclerion partners with Guggenheim for $20M stock sale

Published 07/05/2025, 22:42
Cyclerion partners with Guggenheim for $20M stock sale

Cyclerion Therapeutics (NASDAQ:CYCN), Inc., a biopharmaceutical company with a market capitalization of $8.58 million, has entered into a Sales Agreement with Guggenheim Securities, LLC, according to a recent SEC filing. Under this agreement, Cyclerion may sell up to $20 million of its common stock through Guggenheim Securities, which will act as the sales agent. InvestingPro data shows the company maintains a strong balance sheet with cash exceeding debt, though analysts expect challenging profitability ahead.

The agreement, dated May 7, 2025, specifies that Guggenheim Securities will make reasonable efforts to sell the shares as per Cyclerion’s instructions. The company has agreed to indemnify Guggenheim Securities and will pay a commission of 3% on the gross proceeds from the sale of the shares. The timing appears strategic, as the stock has shown strong momentum with a 39% gain over the past six months, according to InvestingPro data.

The sale of shares is to be conducted as an "at the market" offering, meaning the shares will be sold directly on the Nasdaq Capital Market or other trading markets for the company’s common stock. The transactions will be governed by the rules of the Securities Act of 1933, as amended, and will be made in accordance with a previously filed and effective registration statement on Form S-3.

Cyclerion has clarified that there is no obligation to sell any of the shares and that it retains the right to suspend or terminate the offering at any time. The company also noted that it will adhere to the limitations set forth by General Instruction I.B.6 of Form S-3, which restricts the value of shares sold to no more than one-third of the company’s public float within any 12-month period, provided the public float is under $75 million.

The announcement also highlighted that the SEC filing and agreement should not be considered as an offer to sell or the solicitation of an offer to buy the shares, and that any sales would be subject to legal requirements in various jurisdictions.

Ropes & Gray LLP, legal counsel to Cyclerion, has provided an opinion on the sale of the shares, and this opinion, along with its consent, is included as an exhibit to the SEC filing.

This news is based on a press release statement and is intended for informational purposes. No offer of sale or solicitation of an offer to buy shares is being made in this communication.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.